Adjusted EBITDA improved to NOK -12.1 million, from NOK -13.6 million in the prior-year period, and the company said it has a positive revenue outlook for the remainder of 2026. Arctic Bioscience also secured NOK 15 million in long-term financing during the half-year.

On the clinical side, the company highlighted multiple peer-reviewed publications and conference presentations on HRO350, an oral herring-roe-oil-derived candidate in development for mild-to-moderate psoriasis, which it says build on and reinforce the earlier HeROPA trial results. The update follows a data publication earlier in August in Frontiers in Medicine showing reduced inflammatory biomarkers in psoriasis patients receiving herring roe oil in the company’s Haukeland trial.